Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer
- 7 October 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 59 (4), 529-540
- https://doi.org/10.1007/s00262-009-0769-5
Abstract
Defects in HLA class I antigen processing machinery (APM) component expression often have a negative impact on the clinical course of tumors and on the response to T cell-based immunotherapy. Since only scant information is available about the frequency and clinical significance of HLA class I APM component abnormalities in prostate cancer, the APM component expression pattern was analyzed in 59 primary prostate carcinoma, adjacent normal tissues, as well as in prostate carcinoma cell lines. The IFN-γ inducible proteasome subunits LMP2 and LMP7, TAP1, TAP2, calnexin, calreticulin, ERp57, and tapasin are strongly expressed in the cytoplasm of normal prostate cells, whereas HLA class I heavy chain (HC) and β2-microglobulin are expressed on the cell surface. Most of the APM components were downregulated in a substantial number of prostate cancers. With the exception of HLA class I HC, TAP2 and ERp57 not detectable in about 0.5% of tumor lesions, all other APM components were not detected in at least 21% of lesions analyzed. These APM component defects were associated with a higher Gleason grade of tumors and an early disease recurrence. Prostate carcinoma cell lines also exhibit a heterogeneous, but reduced constitutive APM component expression pattern associated with lack or reduced HLA class I surface antigens, which could be upregulated by IFN-γ. Our results suggest that HLA class I APM component abnormalities are mainly due to regulatory mechanisms, play a role in the clinical course of prostate cancer and on the outcome of T cell-based immunotherapies.Keywords
This publication has 54 references indexed in Scilit:
- Synergistic anti-tumor effect of combination radio- and immunotherapy by electro-gene therapy plus intra-tumor injection of dendritic cellsCancer Letters, 2008
- Advances in Specific Immunotherapy for Prostate CancerEuropean Urology, 2008
- Pitfalls or Promise in Prostate Cancer Immunotherapy—Which Is Winning?The Cancer Journal, 2008
- Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinomaCancer Immunology, Immunotherapy, 2007
- Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanismsTissue Antigens, 2007
- Calreticulin exposure increases cancer immunogenicityNature Biotechnology, 2007
- Development and characterization of human constitutive proteasome and immunoproteasome subunit‐specific monoclonal antibodiesTissue Antigens, 2005
- Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patientsInternational Journal of Cancer, 2005
- Down-Regulation of HLA Class I Antigen Processing Molecules: An Immune Escape Mechanism of Renal Cell Carcinoma?Journal of Urology, 2004
- Purification of Murine IgG Monoclonal Antibodies by Precipitation with Caprylic Acid: Comparison with Other Methods of PurificationHybridoma, 1989